PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. · Breast Care · 2016
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Cited by 30,845 works. doi:10.1159/000453569 Open-access PDF
Authors
- Andreas Daniel Hartkopf
- Florin‐Andrei Taran
- Markus Wallwiener
- Christina Barbara Walter
- Eva‐Maria Grischke
- Sara Yvonne Brucker
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Comprehensive molecular portraits of human breast tumours
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer